NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

Aclaris Therapeutics logo
$2.17 -0.03 (-1.36%)
Closing price 04:00 PM Eastern
Extended Trading
$2.12 -0.04 (-2.07%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Key Stats

Today's Range
$2.11
$2.21
50-Day Range
$2.20
$3.94
52-Week Range
$0.95
$5.17
Volume
726,131 shs
Average Volume
868,397 shs
Market Capitalization
$155.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Buy

Company Overview

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
78th Percentile Overall Score

ACRS MarketRank™: 

Aclaris Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 171st out of 965 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aclaris Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aclaris Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Aclaris Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.81) to ($0.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aclaris Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aclaris Therapeutics is -4.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aclaris Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Aclaris Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.49% of the outstanding shares of Aclaris Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Aclaris Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Aclaris Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.49% of the outstanding shares of Aclaris Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Aclaris Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Aclaris Therapeutics has recently increased by 15.63%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Aclaris Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Aclaris Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for ACRS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aclaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,499,998.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Aclaris Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Aclaris Therapeutics' insider trading history.
Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRS Stock News Headlines

Aclaris Therapeutics announces publication describing properties of ATI-2138
Urgent update to my gold outlook
Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett’s insights show you how to position yourself for wealth in 2025. Don’t wait—these opportunities can disappear fast!
Aclaris Therapeutics (NASDAQ:ACRS) Cut to "Sell" at StockNews.com
Research Analysts Set Expectations for ACRS FY2025 Earnings
See More Headlines

ACRS Stock Analysis - Frequently Asked Questions

Aclaris Therapeutics' stock was trading at $2.48 at the beginning of the year. Since then, ACRS stock has decreased by 12.5% and is now trading at $2.17.
View the best growth stocks for 2025 here
.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The biotechnology company had revenue of $4.35 million for the quarter, compared to analysts' expectations of $8.31 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 40.26% and a negative net margin of 136.65%.

Top institutional investors of Aclaris Therapeutics include Connor Clark & Lunn Investment Management Ltd. (1.27%), Geode Capital Management LLC (1.11%), Peapod Lane Capital LLC (0.57%) and Assenagon Asset Management S.A. (0.56%). Insiders that own company stock include Braden Michael Leonard, Neal Walker, Anand Mehra, Andrew N Schiff, Joseph Monahan, James Loerop, Douglas J Manion, Kevin Balthaser and Frank Ruffo.
View institutional ownership trends
.

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aclaris Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Netflix (NFLX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/06/2024
Today
2/12/2025
Next Earnings (Estimated)
2/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACRS
Employees
100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+405.7%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Net Income
$-88,480,000.00
Net Margins
-136.65%
Pretax Margin
-138.00%

Debt

Sales & Book Value

Annual Sales
$31.25 million
Book Value
$2.22 per share

Miscellaneous

Free Float
66,859,000
Market Cap
$155.36 million
Optionable
Optionable
Beta
0.50

Social Links

7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ACRS) was last updated on 2/12/2025 by MarketBeat.com Staff
From Our Partners